Fig. 2.

The identity of the mutation at Thr-315 and Phe-317 determines the sensitivity or resistance of BCR-ABL to each of the kinase inhibitors. (A) Western blot analysis of stable Ba/F3 clones expressing the indicated BCR-ABL p210 isoform. In each case, cells were normalized by cell count and lysed in equal volumes of lysis buffer after exposure to the indicated concentration of drug for 3–4 h. Western blots were analyzed with antibody to antiphosphotyrosine (anti-PY), ABL, and β-actin. Comparison of growth inhibition by BMS-354825 and imatinib on mutations at Thr-315 (B) and Phe-317 (C). WT p210 is plotted as a control.